Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

COMPUGROUP MEDICAL SE & CO. KGAA

(COP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : CompuGroup Medical announces medium-term targets for EBITDA-margin for the first time and confirms 2021 guidance

09/14/2021 | 10:48am EST

DGAP-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Miscellaneous CompuGroup Medical announces medium-term targets for EBITDA-margin for the first time and confirms 2021 guidance 2021-09-14 / 16:47 The issuer is solely responsible for the content of this announcement.

----------------------------------------------------------------------------------------------------------------------- . Adjusted EBITDA margin expected to increase to approximately 25 % in 2023 and to approximately 27 % in2025 . Organic revenue growth year-on-year of 5 % and more per year expected for the years 2021 through 2025 . Annual guidance for 2021 confirmed . Digitization in the healthcare sector accelerates growth

Koblenz. CompuGroup Medical SE & Co. KGaA, one of the leading e-health providers in the world, announces medium-term targets for the development of the adjusted EBITDA-margin for the first time. The medium-term growth target of increasing group revenues year-on-year organically by 5 % and more per year from 2021 through 2025 had been published previously. In addition, the Managing Directors have now also adopted targets for the medium-term increase in adjusted EBITDA margin for the first time. Accordingly, CompuGroup Medical aims to increase the adjusted EBITDA margin to approximately 25 % in 2023 and to approximately 27 % in 2025. Further information on medium-term targets will be presented at the virtual Capital Markets Day tomorrow.

In light of the ongoing investment program announced in December 2020 to accelerate growth, the Managing Directors confirm the full year 2021 guidance. CompuGroup Medical expects revenues in 2021 to be in a range of EUR 1 billion and EUR 1.04 billion as well as adjusted EBITDA between EUR 210 million and EUR 230 million.

Digital transformation in healthcare accelerates growth "Digitization is finally happening in healthcare, reinforced by the pandemic. Our customers' world is transforming rapidly. CompuGroup?Medical is ideally positioned to support doctors, pharmacies, hospitals and other healthcare professionals on their path towards digitization", says CEO Dr. Dirk Wössner. "Governments across Europe have realized the need to digitize and modernize the healthcare space, and the transformation is gaining speed. We are ready to capture this fantastic opportunity. Organic growth has already accelerated in the first half of this year, and we confirm our ambition to achieve an organic year-on-year revenue growth of 5 % and more per year from 2021 through 2025." CFO Michael Rauch adds: "This year we have significantly stepped up our investments to accelerate our organic growth. At the same time, we are targeting a clear path towards increasing profitability post the investment phase we announced in December 2020. We expect to be back at former levels of profitability with an adjusted EBITDA margin of approximately 25 % in 2023 and to increase the level even further going forward with a target margin of approximately 27 % by 2025."

Further information on the virtual Capital Markets Day 2021 will be available for download on the company website www.cgm.com/ir. Forward-Looking Statements This release contains "forward-looking statements". Forward-looking statements may differ significantly from future results and often in fact differ. All forward-looking statements reflect CompuGroup Medical SE & Co. KGaA's (CompuGroup Medical) current view on future events and are subject to risks relating to future events and other risks, uncertainties and assumptions regarding CompuGroup Medical's business, financial position, results of operations, liquidity, prospects, growth or strategy. Forward-looking statements should always be considered from the perspective of the date on which they are made. CompuGroup Medical as well as their affiliated companies expressly disclaim any obligation to update, review or adjust any forward-looking statements contained in this release as a result of new information, future developments or other reasons. Any responsibility for the future accuracy of the opinions expressed in this release or the actual occurrence of the forecast developments is expressly excluded. About CompuGroup Medical SE & Co. KGaA CompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 837 million in 2020, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical's services are based on a unique customer base of more than 1.6 million users, including doctors, dentists, pharmacists, and other healthcare professionals in inpatient and outpatient facilities. With locations in 18 countries and products in 56 countries worldwide, CompuGroup Medical is the e-health company with one of the highest coverages among healthcare professionals. Approximately 8,500 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system. Contact for media representatives: Michael Franz Head of Brand Communication P +49 (0) 261 8000-6100 F +49 (0) 261 8000-3100 E-mail: press@cgm.com Contact for analysts and investors: Claudia Thomé Corporate Vice President Investor Relations P +49 (0) 261 8000-7030 F +49 (0) 261 8000-3200 E-mail: claudia.thome@cgm.com

-----------------------------------------------------------------------------------------------------------------------

2021-09-14 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

-----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      CompuGroup Medical SE & Co. KGaA 
              Maria Trost 21 
              56070 Koblenz 
              Germany 
Phone:        +49 (0)261 8000 7030 
Fax:          +49 (0)261 8000 3200 
E-mail:       investor@cgm.com 
Internet:     www.cgm.com 
ISIN:         DE000A288904 
WKN:          A28890 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1233339 
 
End of News   DGAP News Service 
=------------ 

1233339 2021-09-14

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1233339&application_name=news

(END) Dow Jones Newswires

September 14, 2021 10:47 ET (14:47 GMT)

All news about COMPUGROUP MEDICAL SE & CO. KGAA
06:53aCOMPUGROUP MEDICAL : Downgraded from Neutral to Sell by Morgan Stanley
MD
12/06COMPUGROUP MEDICAL SE & CO. KGAA : Share Buy-Back Program - 1st Interim Announcement
EQ
11/25CompuGroup Medical To Launch $42 Million Share Buyback
MT
11/25COMPUGROUP MEDICAL SE & CO. KGAA : Release of a capital market information
EQ
11/25CompuGroup Medical SE & Co. KGaA adopts resolution on share buy-back program for up to ..
EQ
11/11COMPUGROUP MEDICAL : Gets a Buy rating from Berenberg
MD
11/09COMPUGROUP MEDICAL : Baader Bank remains a Sell rating
MD
11/08COMPUGROUP MEDICAL : Kepler Cheuvreux gives a Neutral rating
MD
11/04CompuGroup Medical SE & Co. KGaA Reports Earnings Results for the Third Quarter and Nin..
CI
11/04COMPUGROUP MEDICAL : Kepler Cheuvreux remains Neutral
MD
More news
Analyst Recommendations on COMPUGROUP MEDICAL SE & CO. KGAA
More recommendations
Financials
Sales 2021 1 022 M 1 155 M 1 155 M
Net income 2021 80,6 M 91,0 M 91,0 M
Net Debt 2021 512 M 578 M 578 M
P/E ratio 2021 45,2x
Yield 2021 0,83%
Capitalization 3 594 M 4 040 M 4 059 M
EV / Sales 2021 4,02x
EV / Sales 2022 3,73x
Nbr of Employees 8 079
Free-Float 48,8%
Chart COMPUGROUP MEDICAL SE & CO. KGAA
Duration : Period :
CompuGroup Medical SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COMPUGROUP MEDICAL SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 68,15 €
Average target price 84,85 €
Spread / Average Target 24,5%
EPS Revisions
Managers and Directors
Dirk W÷ssner Chairman-Management Board & CEO
Philipp von Ilberg Chairman-Supervisory Board
Frank Brecher Chief Technology Officer
Sven Thomas MŘller Vice Chairman & Chief Information Officer
Ulrike Handel Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
COMPUGROUP MEDICAL SE & CO. KGAA-13.30%4 040
ORACLE CORPORATION39.20%246 168
SAP SE11.58%158 639
SERVICENOW, INC.20.52%132 011
CONSTELLATION SOFTWARE INC.34.78%37 321
HUBSPOT, INC.79.70%35 962